{"name":"Omega Funds","permalink":"omega-funds","crunchbase_url":"http://www.crunchbase.com/financial-organization/omega-funds","homepage_url":"http://www.omegafunds.ca","blog_url":"","blog_feed_url":"","twitter_username":"","phone_number":"","description":"fund sponsor","email_address":"","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"tag_list":null,"alias_list":"","created_at":"Wed Jun 17 21:38:34 UTC 2009","updated_at":"Tue Sep 08 11:20:38 UTC 2009","overview":"<p>Strategically advanced, they enable you to benefit from the expertise of institutional portfolio managers all for a minimum investment of $500!\nOmega FundsTM give you the opportunity to diversify your investment portfolio and maximize return potential. </p>","image":{"available_sizes":[[[150,29],"assets/images/resized/0005/9079/59079v1-max-150x150.png"],[[250,49],"assets/images/resized/0005/9079/59079v1-max-250x250.png"],[[450,88],"assets/images/resized/0005/9079/59079v1-max-450x450.png"]],"attribution":null},"offices":[],"relationships":[],"investments":[{"funding_round":{"round_code":"d","source_url":"http://onbiovc.com/elixir-pharmaceuticals-inc-series-d-12m/","source_description":"Elixir Pharmaceuticals, Inc.: Series D $12M","raised_amount":12000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":5,"funded_day":27,"company":{"name":"Elixir Pharmaceuticals","permalink":"elixir-pharmaceuticals","image":{"available_sizes":[[[150,25],"assets/images/resized/0004/9232/49232v1-max-150x150.jpg"],[[250,42],"assets/images/resized/0004/9232/49232v1-max-250x250.jpg"],[[450,75],"assets/images/resized/0004/9232/49232v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"unattributed","source_url":"http://deals.venturebeat.com/2007/03/20/intarcia-restarts-with-50m-for-hepatitis-diabetes-treatments/","source_description":"Intarcia restarts with $50M for hepatitis, diabetes treatments","raised_amount":null,"raised_currency_code":"USD","funded_year":2007,"funded_month":3,"funded_day":20,"company":{"name":"Intarcia Therapeutics","permalink":"intarcia-therapeutics","image":{"available_sizes":[[[150,85],"assets/images/resized/0006/2213/62213v1-max-150x150.png"],[[157,89],"assets/images/resized/0006/2213/62213v1-max-250x250.png"],[[157,89],"assets/images/resized/0006/2213/62213v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"c","source_url":"http://www.fiercebiotech.com/story/oxagen-rounds-26-7m-vc/2009-11-24?utm_medium=rss&utm_source=rss&cmp-id=OTC-RSS-FB0","source_description":"Oxagen rounds up $26.7M in VC","raised_amount":26700000,"raised_currency_code":"USD","funded_year":2009,"funded_month":11,"funded_day":24,"company":{"name":"Oxagen","permalink":"oxagen","image":{"available_sizes":[[[150,45],"assets/images/resized/0006/7578/67578v1-max-150x150.png"],[[152,46],"assets/images/resized/0006/7578/67578v1-max-250x250.png"],[[152,46],"assets/images/resized/0006/7578/67578v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://www.neurotechusa.com/news_events/pr_2006-11-16.asp","source_description":"Neurotechâ„¢, Inc. Completes $35 Million Private Equity Financing","raised_amount":35000000,"raised_currency_code":"USD","funded_year":2006,"funded_month":11,"funded_day":16,"company":{"name":"Neurotech","permalink":"neurotech","image":{"available_sizes":[[[150,47],"assets/images/resized/0008/4292/84292v1-max-150x150.jpg"],[[225,71],"assets/images/resized/0008/4292/84292v1-max-250x250.jpg"],[[225,71],"assets/images/resized/0008/4292/84292v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"unattributed","source_url":"http://www.haaretz.com/print-edition/business/celletra-raises-5-7m-1.153441","source_description":"Celletra raises $5.7m","raised_amount":5700000,"raised_currency_code":"USD","funded_year":2005,"funded_month":3,"funded_day":18,"company":{"name":"Celletra","permalink":"celletra","image":{"available_sizes":[[[150,126],"assets/images/resized/0009/6828/96828v1-max-150x150.png"],[[156,132],"assets/images/resized/0009/6828/96828v1-max-250x250.png"],[[156,132],"assets/images/resized/0009/6828/96828v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://pevc.dowjones.com/article?an=DJFVW00020120507e857s1ios&from=alert&pid=32&ReturnUrl=http%3a%2f%2fpevc.dowjones.com%3a80%2farticle%3fan%3dDJFVW00020120507e857s1ios%26from%3dalert%26pid%3d32","source_description":"Denmark's Egalet Grabs $14.3M, New CEO For Abuse-Resistant Drugs","raised_amount":14300000,"raised_currency_code":"USD","funded_year":2012,"funded_month":5,"funded_day":7,"company":{"name":"Egalet","permalink":"egalet","image":{"available_sizes":[[[150,46],"assets/images/resized/0018/8369/188369v1-max-150x150.jpg"],[[250,77],"assets/images/resized/0018/8369/188369v1-max-250x250.jpg"],[[298,92],"assets/images/resized/0018/8369/188369v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"a","source_url":"http://www.pehub.com/172755/visterra-adds-13m-wrap-up-series-a/","source_description":"Visterra Adds $13M to Wrap Up Series A","raised_amount":13000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":11,"funded_day":9,"company":{"name":"Visterra","permalink":"visterra","image":{"available_sizes":[[[150,48],"assets/images/resized/0009/6987/96987v1-max-150x150.png"],[[250,80],"assets/images/resized/0009/6987/96987v1-max-250x250.png"],[[250,80],"assets/images/resized/0009/6987/96987v1-max-450x450.png"]],"attribution":null}}}}],"milestones":[],"providerships":[],"funds":[],"video_embeds":[],"external_links":[]}